Harbour BioMed Email Formats

Biotechnology Research • Cambridge, Massachusetts, United States • 101-200 Employees

Harbour BioMed Email Formats

Harbour BioMed uses 1 email format. The most common is {first name}.{last name} (e.g., john.doe@harbourbiomed.com), used 100% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@harbourbiomed.com	100%

Key Contacts at Harbour BioMed

Daniel Liangsi Tang

Senior Director - Finance Controller

Robert Kamen

Member Board Of Directors

Luyin Ding

Director, Clinical Research Physician, Oncology

Yu Wang

Director Of Business Development

Xicao Niu

Head Of Clinical Data Management, Senior Director

Yiping Rong

Cso, Executive Board Of Director

Qing Wang

Director, Head Of Programming

Jimmy Rong

Associate Research Director

Maggie Zhou

Executive Director, Head Of Corporate Operation

Wang Chao

Associate Director

Company overview

Headquarters	1 Broadway, Fl 14, Cambridge, Massachusetts 02142, US
Phone number	+1862153399168
Website	harbourbiomed.com
NAICS	541714
SIC	283
Keywords	Immunology, Immuno-Oncology, Transgenic Mouse Technology, B-Cell Cloning
Employees	101-200
Socials

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions. The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com